Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06041269 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
A Phase 2 study of Rheumatoid Arthritis, sponsored by AnaptysBio.
- Active
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT06041269: Active Phase 2 study of Rheumatoid Arthritis, sponsored by AnaptysBio.
NCT06041269 is a Phase 2 study of Rheumatoid Arthritis that is active but no longer recruiting, run by AnaptysBio. The registered enrollment target is 420 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06041269, a Phase 2 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by AnaptysBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Primary Outcome
The DAS28-CRP is a validated composite assessment that assesses RA disease activity based on tender and swollen joint counts of 28 joints
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rosnilimab
Study Locations (20)
Florida
- AnaptysBio Investigative Site 10-103 - Aventura
- AnaptysBio Investigative Site 10-141 - Avon Park
- AnaptysBio Investigative Site 10-118 - Boynton Beach
- AnaptysBio Investigative Site 10-125 - Daytona Beach
- AnaptysBio Investigative Site 10-122 - Homestead
- Anaptys Bio Investigative Site 10-142 - Miami
- AnaptysBio Investigative Site 10-140 - Miami
- AnaptysBio Investigative Site 10-102 - Miami
- AnaptysBio Investigative Site 10-124 - Plantation
California
- AnaptysBio Investigative Site 10-105 - Covina
- Anaptys Bio Investigative Site 10-119 - Rancho Mirage
- AnaptysBio Investigative Site 10-113 - San Diego
- AnaptysBio Investigative Site 10-127 - San Francisco
- AnaptysBio Investigative Site 10-136 - Temecula
- AnaptysBio Investigative Site 10-133 - Upland
- AnaptysBio Investigative Site 10-112 - Whitter
Arizona
- AnaptysBio Investigative Site 10-132 - Flagstaff
- AnaptysBio Investigative Site 10-130 - Glendale
- AnaptysBio Investigative Site 10-129 - Phoenix
- AnaptysBio Investigative Site 10-131 - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
What the registry record for NCT06041269 still lists
NCT06041269 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06041269 names 20 study sites across 3 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06041269 about?
NCT06041269 is a clinical study titled "A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)". RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
What is the current status of trial NCT06041269?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2023-08-31. Estimated completion is 2025-05-30.
What conditions does trial NCT06041269 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06041269?
The interventions under investigation include: Placebo (DRUG), Rosnilimab (DRUG).
Who is sponsoring clinical trial NCT06041269?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06041269 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06041269's enrollment target sits among peer trials
420 45th of 197 higher than 153 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI